BALAXI PHARMACEUTICALS
Quarterly Results Analysis [Dec2023]
BALAXI PHARMACEUTICALS Quarterly Results
Consolidated | Dec2023 Audited |
Sep2023 Audited |
Jun2023 UnAudited |
Mar2023 UnAudited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹61 Cr | ₹55 Cr | ₹66 Cr | ₹81 Cr | ₹87 Cr | ₹86 Cr | ₹83 Cr | ₹89 Cr |
Expenses | ₹47 Cr | ₹44 Cr | ₹57 Cr | ₹68 Cr | ₹71 Cr | ₹72 Cr | ₹69 Cr | ₹78 Cr |
Operating Income | ₹14 Cr | ₹11 Cr | ₹9 Cr | ₹13 Cr | ₹15 Cr | ₹15 Cr | ₹14 Cr | ₹11 Cr |
Other Income | ₹0 Cr | ₹0 Cr | ₹-1 Cr | ₹0 Cr | ₹-5 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Profit Before Tax | ₹14 Cr | ₹16 Cr | ₹-39 Cr | ₹11 Cr | ₹11 Cr | ₹19 Cr | ₹17 Cr | ₹15 Cr |
Profit After Tax | ₹14 Cr | ₹14 Cr | ₹-41 Cr | ₹8 Cr | ₹8 Cr | ₹15 Cr | ₹14 Cr | ₹13 Cr |
EPS | ₹13.29 | ₹14.10 | ₹-40.41 | ₹7.96 | ₹8.21 | ₹15.49 | ₹14.15 | ₹12.71 |
Industry Peers & Returns | 1W | 1M | 1Y |
BALAXI PHARMACEUTICALS | -2.6% | 3.2% | 13.4% |
ADANI ENTERPRISES | -7.2% | -12.4% | 56.4% |
REDINGTON | -4.5% | -6% | 21.6% |
HONASA CONSUMER | -0.9% | 4% | NA |
MMTC | -4.8% | -8.3% | 152.6% |
MSTC | -8.6% | -11.8% | 194.4% |
LLOYDS ENTERPRISES | -8.2% | 8.1% | 328% |
VERITAS (INDIA) | -6.2% | 26% | 928.6% |
NOVARTIS INDIA | 3% | 2.3% | 78.7% |
BALAXI PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 11.08 % |
Y-o-Y | -29.79 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹61 Cr | 11.08 | |
Sep2023 | ₹55 Cr | -17.03 | |
Jun2023 | ₹66 Cr | -18.25 | |
Mar2023 | ₹81 Cr | -6.82 | |
Dec2022 | ₹87 Cr | 0.23 | |
Sep2022 | ₹86 Cr | 4.35 | |
Jun2022 | ₹83 Cr | -7.09 | |
Mar2022 | ₹89 Cr | - |
BALAXI PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 26.90 % |
Y-o-Y | -10.67 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹14 Cr | 26.90 | |
Sep2023 | ₹11 Cr | 21.75 | |
Jun2023 | ₹9 Cr | -30.62 | |
Mar2023 | ₹13 Cr | -16.68 | |
Dec2022 | ₹15 Cr | 3.65 | |
Sep2022 | ₹15 Cr | 7.31 | |
Jun2022 | ₹14 Cr | 22.45 | |
Mar2022 | ₹11 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 14.23 % |
Y-o-Y | 27.24 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 22.47% | 14.23 | |
Sep2023 | 19.67% | 46.79 | |
Jun2023 | 13.4% | -15.14 | |
Mar2023 | 15.79% | -10.59 | |
Dec2022 | 17.66% | 3.40 | |
Sep2022 | 17.08% | 2.83 | |
Jun2022 | 16.61% | 31.83 | |
Mar2022 | 12.6% | - |
BALAXI PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -5.79 % |
Y-o-Y | 65.20 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹14 Cr | -5.79 | |
Sep2023 | ₹14 Cr | Positive | |
Jun2023 | ₹-41 Cr | Negative | |
Mar2023 | ₹8 Cr | -1.59 | |
Dec2022 | ₹8 Cr | -46.86 | |
Sep2022 | ₹15 Cr | 9.46 | |
Jun2022 | ₹14 Cr | 11.31 | |
Mar2022 | ₹13 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -15.21 % |
Y-o-Y | 135.37 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 22.36 % | -15.21 | |
Sep2023 | 26.37 % | Positive | |
Jun2023 | -62.68 % | Negative | |
Mar2023 | 10.04 % | 5.68 | |
Dec2022 | 9.5 % | -47.02 | |
Sep2022 | 17.93 % | 4.92 | |
Jun2022 | 17.09 % | 19.76 | |
Mar2022 | 14.27 % | - |
BALAXI PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -5.74 % |
Y-o-Y | 61.88 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹13.29 | -5.74 | |
Sep2023 | ₹14.1 | Positive | |
Jun2023 | ₹-40.41 | Negative | |
Mar2023 | ₹7.96 | -3.05 | |
Dec2022 | ₹8.21 | -47.00 | |
Sep2022 | ₹15.49 | 9.47 | |
Jun2022 | ₹14.15 | 11.33 | |
Mar2022 | ₹12.71 | - |
You may also like the below Video Courses
ADANI ENTERPRISES LTD vs REDINGTON LTD vs HONASA CONSUMER LTD
MMTC LTD vs MSTC LTD vs LLOYDS ENTERPRISES LTD